Commentary
Video
Author(s):
Christian Marth, MD, PhD, discusses next steps with pembrolizumab and lenvatinib for use in the advanced or recurrent endometrial cancer treatment paradigm.
Dostarlimab With Carboplatin/Paclitaxel Shows Survival Benefits in dMMR/MSI-H Endometrial Cancer
Monk and Tarantino Describe the Investigation of B7-H4 Vedotin–Directed ADCs in Gynecologic and Breast Cancers
Overcoming Adversity and Achieving the American Dream in Cancer Care
Naumann Discusses Notable Research Efforts in Endometrial Cancer
Long-Term Findings Clarify Role of Estrogen Therapy on Ovarian/Endometrial Cancer Incidence
Mirvetuximab Soravtansine Plus Pembrolizumab Generates Reponses in pMMR FRα+ Serous Endometrial Cancer
Axi-Cel Shows Safety, Clinical Activity in R/R Primary and Secondary CNS Lymphomas
Amphiphile Lymph Node–Targeted Vaccine Is Safe and Bolsters T-Cell Responses in MRD+ PDAC and CRC
JNJ-6420 Elicits Responses in mCRPC, But Safety Concerns Arise
ARV-766 Demonstrates Clinical Activity in AR LBD–Mutated Metastatic CRPC